摘要
目的观察长春瑞滨联合顺铂方案在复发转移性乳腺癌治疗中的近期疗效和不良反应。方法回顾性分析62例复发转移性乳腺癌患者临床资料,给予长春瑞滨联合顺铂治疗。化疗过程中记录不良反应,评价疗效。结果治疗总有效率为59.68%(37/62),临床总获益率为90.32%(56/42),不良反应主要为骨髓抑制及胃肠道反应。结论 NP方案治疗复发转移性乳腺癌疗效确切,不良反应患者能够耐受。
Objective To observe the short-term efficacy and side effects of vinorelbine combined with cisplatin regimen in the treatment of patients with relapsed and metastatic breast cancer. Methods Clinical materials of 62 patients with relapsed and metastatic breast cancer were analyzed retrospectively, and they were treated with vinorelbine and cisplatin. Adverse events were recorded and efficacy was evaluated. Results The total effective rate was 59.68% (37/62). The total clinical benefit rate was 90.32% (56/42). The main adverse reactions were myelosuppression and gastrointestinal response. Conclusion NP regimen is effective in the treatment of patients with relapsed and metastatic breast cancer, and patients can tolerate the adverse reactions.
出处
《实用临床医药杂志》
CAS
2017年第3期68-70,共3页
Journal of Clinical Medicine in Practice
基金
辽宁省卫生厅资助基金(1229812)
关键词
乳腺癌
NP方案
耐受
不良反应
breast cancer
NP regimen
tolerance
adverse reaction